Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ESMO 2026 | EIK1003-001: EIK1003 plus abiraterone in metastatic prostate cancer

Name: EIK1003-001: EIK1003 plus abiraterone in metastatic prostate cancer
Uploaded: 2026-10-24T00:00:00Z
Duration: 1 min 20 s

Guru Sonpavde • 24 Oct 2026

ESMO 2026

Genitourinary Cancer Prostate Cancer EIK1003

EIK1003-001

Guru Sonpavde, MD, AdventHealth Cancer Institute, Orlando, FL, discusses results from the Phase I/II EIK1003-001 study (NCT06253130) of EIK1003, a PARP1-selective inhibitor, combined with abiraterone and prednisone in heavily pretreated patients with metastatic prostate cancer harboring homologous recombination repair mutations. The combination showed a tolerable safety profile with limited hematological toxicity, favorable pharmacokinetics and encouraging antitumor activity across all dose levels. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.